VERA
Vera Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$28.92
+3.73%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -87.1%
- EBIT
- -76.1%
- EPS
- -58.0%
- Free cash flow
- -60.4%
- Operating cash flow
- -82.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +12.2%
- EPS
- +16.0%
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- -88.7%
- Net income
- -96.9%
- EPS
- -69.5%
- Free cash flow
- -78.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026